New treatment for MS on the NHS approved by NICE

Credit: Getty Images/PeopleImages

By Olivia Bowthorpe

People in England with highly active relapsing-remitting multiple sclerosis who have not responded to standard treatment will soon have access to another high efficacy therapy.

The drug natalizumab can now be used for adults whose MS remains active after at least one disease-modifying therapy and for whom cladribine is not suitable, says NICE in final draft guidance.